1. Introduction {#sec0001}
===============

Hereditary multiple exostoses (HME) is one of the commonest inherited musculoskeletal conditions with an incidence of 1 in 50,000 [@bib0001]. In this condition, multiple cartilage-capped exostoses develop during childhood and ossify when skeletal growth is complete [@bib0001], [@bib0002]. These occur primarily at long bone metaphyses. Loss of heterozygosity in exostosin-1(EXT1) and exostosin-2(EXT2) genes have been implicated to cause HME [@bib0002], [@bib0003]. Males are more commonly and severely affected due to incomplete EXT1 penetrance in females [@bib0004]. The most serious complication of HME is chondrosarcoma transformation [@bib0005], [@bib0006], [@bib0007]. Numerous authors have proposed a screening programme using X-ray or magnetic resonance imaging (MRI) to identify chondrosarcoma transformation in HME early [@bib0007], [@bib0008], [@bib0009]. There are several reasons for this. Firstly, even though most chondrosarcomas transformations are low-grade, their size and location close to major neurovascular bundles at diagnosis makes wide excision difficult. This is especially so with pelvic tumours [@bib0005], [@bib0010]. Early diagnosis reduces the need for debilitating surgery. Secondly, assuming the lowest reported lifetime risk of chondrosarcoma at 2%, most of which occurs in the 2nd-4th decade of life, the annual risk in this age group would be 0.1% [@bib0009]. The figure increases in EXT1 male patients and becomes comparable to the occurrence of breast cancer at 0.2% per annum, for which there are currently widespread screening programs [@bib0011]. The risk of malignant transformation increases in males and having an EXT1 mutation [@bib0001], [@bib0005], [@bib0012]. However, the literature-quoted incidences of malignant transformation by sex, genotype and anatomical distribution, which are needed to guide a screening model, are highly variable [@bib0001], [@bib0012], [@bib0013]. A screening model to detect chondrosarcoma transformation in HME has never been developed before. This study hence aims to: 1) systematically review the literature for incidence of chondrosarcoma transformation by age, sex, genotype and anatomical distribution. 2) Propose a preliminary screening model for HME patients based on literature findings. 3) Evaluate the clinical- and cost-effectiveness of this screening model. 4) Compare the cost-effectiveness of MRI and X-rays as screening modalities we hypothesise that a MRI screening program for all HME patients is feasible if targeted at select anatomical sites. Our study, while not intended to give definitive guidance over whether HME screening should be established, will provide important parameters for more detailed analyses to be performed. In addition, this analysis may contribute to the debate about whether screening programs should be established in similar familial neoplastic traits such as Familial Retinoblastoma (Rb) [@bib0014].

2. Material and methods {#sec0002}
=======================

2.1. Search strategy {#sec0003}
--------------------

The following databases were searched in Feb 2018: MEDLINE via PubMed (1948-February2018), EMBASE via PubMed (1980-February 2018), CINHAL via Ebsco host (1926-February 2018). MeSh and keyword headings used were: multiple hereditary exostos\* or multiple cartilaginous exostos\* or diaphyseal aclasis\* or multiple osteochondroma\*; chondrosarcoma\* or bone tumour\*; adult\* or child\*or infant\*; male\*or female\* or gender\*; exostosin-1\*or exostosin-2\*([Appendix A.1](#sec0024){ref-type="sec"}). Hand-searches were performed on reference lists of retrieved reports, abstracts at the last 6 years of key conferences (*European Sarcoma Conference* and *MHE International Research Conference*), and key journals (*Journal of Bone and Joint surgery American volume,* its *British volume* and *Cancer)*. A further two journals, *Spine* and *Journal of Neurosurgery,* were hand-searched because reviewers recognised that orthopaedic journals were less likely to report spinal exostoses. In addition, a citation search was performed using Web of Science.

We contacted authoritative researchers in the field to locate unpublished data. Attempts were also made to contact authors of potentially eligible studies presented in the 1980s but this was unsuccessful.

2.2. Selection criteria {#sec0004}
-----------------------

One reviewer screened the titles and abstracts of all identified reports. Potentially relevant studies were than retrieved and selection criteria applied: 1) the study was a longitudinal study of HME within a general population; 2) demographics of chondrosarcoma transformation were reported.

As there was an expectation that few reports would meet these criteria, an expanded criteria was planned to include disease-specific case-control studies, cross-sectional studies and case series. Selection criteria for case-control and cross-sectional studies were that results reported on demographics of chondrosarcoma transformation. The selection criteria for case series was 1) \> 30 cases of HME reported per case series 2) demographics of chondrosarcoma transformation were reported.

2.3. Data extraction and data analysis {#sec0005}
--------------------------------------

One reviewer extracted data onto standardised data extraction forms. Any uncertainty was discussed with a second reviewer and disagreements resolved by consensus. The reviewers were not blinded to the author names, institutions or results of the study. Due to significant heterogeneity in methods of reporting, no attempt was made to pool and statistically analyse the data. Because of resource constraints, authors were not contacted where data was incomplete. This has been indicated in [Appendix A.2.](#tbl0003){ref-type="table"}

Methodological quality of all studies was evaluated using relevant Newcastle-Ottawa Scale(NOS) for nonrandomised studies [@bib0015]. A detailed description of NOS is found elsewhere.

2.4. Screening model structure and measured outcomes {#sec0006}
----------------------------------------------------

The base-population of HME patients used in this model was calculated using incidence estimates of 1 in 50,000 and an England & Wales population of 57.5million. HME patients were assumed to live average UK life expectancies of 80 years [@bib0016]. The effects of screening different subgroups of HME patients were compared using these outcomes: (a) cost per life-year gained (b) incremental cost-effectiveness ratio (ICER) for the more costly strategy (c) radiation-induced cancers in X-ray screening (d) psychological impact of false-positives. In line with UK National Institute of Health and Clinical Excellence (NICE) recommendations, a 3.5% annual discount rate was applied to all outcomes [@bib0017].

2.5. Values of key model parameters {#sec0007}
-----------------------------------

Postulating from studies of primary pelvic chondrosarcomas where lesions \< 10 cm at diagnosis gave an 18% improved survival rate over lesions \> 10 cm, we assume that our model confers an 18% relative survival advantage in all HME subgroups by detecting lesions before they reach 10 cm [@bib0018].

On plain radiographs, progressive exosteal growth after growth plate fusion or a change in surface delineation predicts chondrosarcoma transformation [@bib0019]. MRI validation studies have shown that a cartilage cap thickness \> 2 cm predicts secondary chondrosarcomas with a sensitivity of 98% [@bib0020]. Model costs for the basic screen, diagnostic workup and surgeon examinations were obtained from NHS Reference Costs 2013/14 [@bib0021]. Personal time cost for the screening visit was estimated from the Annual Survey of Hours and Earnings 2014 [@bib0022]. All costs were measured in U.K pounds sterling ([Appendix A.3](#tbl0004){ref-type="table"}).

2.6. Evaluating cost-effectiveness {#sec0008}
----------------------------------

NICE has identified a willingness-to-pay threshold value of £30,000 per life-year gained [@bib0017]. We also compared our cost-effectiveness analysis to the cost per life-year gained in the UK NHS breast cancer screening programme (NHSBSP) of £7357 [@bib0023].

3. Results {#sec0009}
==========

3.1. Characteristics of selected studies {#sec0010}
----------------------------------------

The literature search identified only 1 relevant longitudinal general population study that satisfied our initial criteria [@bib0012]. Because of the paucity of data, the criteria was broadened and 9 disease-specific retrospective case controls (including 1 unpublished study) [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0019], [@bib0024], [@bib0025], [@bib0026], 5 disease-specific cross-sectional studies [@bib0001], [@bib0013], [@bib0027], [@bib0028], [@bib0029] and 3 case series met this inclusion criteria [@bib0030], [@bib0031], [@bib0032]. A total of 18 studies with 2509 HME patients were included in this systematic review. There were 3 studies where no chondrosarcoma was identified [@bib0012], [@bib0025], [@bib0032]. [Appendix A.2](#tbl0003){ref-type="table"} shows all studies that met inclusion criteria. Using NOS, the studies varied widely in methodological quality, with no study gaining the maximum of 5 stars, 3(17%) gaining 4 stars [@bib0030], [@bib0031], 6(33%) gaining 3 stars [@bib0005], [@bib0007], [@bib0019], [@bib0024], [@bib0026], [@bib0032] and 9(50%) gaining only 2 stars [@bib0001], [@bib0004], [@bib0006], [@bib0012], [@bib0013], [@bib0025], [@bib0027], [@bib0028], [@bib0029]. The highest scoring studies were unexpectedly case series reports [@bib0030], [@bib0031]. Full scoring is shown in [Appendix A.4](#tbl0005){ref-type="table"}.

3.2. Results of literature review {#sec0011}
---------------------------------

Studies on the incidence of chondrosarcoma transformation produced widely disparate estimates ranging from 0.88% to 25.1% ([Appendix B.1](#fig0003){ref-type="fig"}). The contributing outliers were both studies from the Mayo clinic [@bib0013], [@bib0027]. Excluding these outliers, the incidence of chondrosarcomas in the remaining 15 studies averaged 3.9%. On average, 80.1% of chondrosarcoma transformation occurred before age 40, with 75.2% taking place between ages20-40. This is in contrast to primary chondrosarcomas, where 65% of cancers occur between ages30-60 [@bib0018] ([Fig. 1A](#fig0001){ref-type="fig"}).Fig. 1A. Age distribution of chondrosarcoma transformation secondary to HME. This has been compared to the age distribution of primary chondrosarcomas. B. Anatomic distribution of the 852 chondrosarcomas. This is expressed as absolute numbers of exostoses, with percentage in brackets.Fig. 1.

A total of 852 chondrosarcomas developed in the 18 studies. There was a striking propensity for flat bones to undergo chondrosarcoma transformation, with the pelvis accounting for 47.9% of cancers the proximal femur 8.3% and the scapula 12.3%. 87.2% of chondrosarcomas were concentrated in the appendicular skeleton. The ribs and spine accounted for 12.8% of chondrosarcomas. ([Fig. 1B](#fig0001){ref-type="fig"}).

On average, 6.3% of males and 4.6% of females developed chondrosarcomas. When the 2 studies from the Mayo Clinic were excluded, percentages of males and females developing chondrosarcoma became 4.0% and 2.7% respectively. Several studies have suggested that the EXT1 cohort would be at 1.5--2 times greater risk of malignant change than in the un-stratified HME cohort, we have adopted the lower figure of 1.5 times in our model for EXT1 individuals and 2.25 times for male EXT1 individuals.

In the Mayo Clinic studies, the survival rate for secondary chondrosarcomas at 20 years was 75% [@bib0013], [@bib0027]. There was no specific literature on survival rates for chondrosarcomas in HME subgroups. We hence assumed the survival rates for secondary chondrosarcomas in EXT1 patients and EXT1 male patients to reflect that of the general HME population respectively.

3.3. Structure of the HME screening model {#sec0012}
-----------------------------------------

This simulates the experiences of a hypothetical cohort of 1150 HME patients attending screening between ages 20--40. [Fig. 2](#fig0002){ref-type="fig"} shows the screening model that was developed. Three annual screening strategies targeting different groups of HME patients were evaluated: (a) all HME patients, (b) HME patients with EXT1 genotype, and (c) HME male patients only with EXT1 genotype [@bib0001], [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0012], [@bib0013], [@bib0013], [@bib0024], [@bib0025], [@bib0026], [@bib0027], [@bib0028], [@bib0029], [@bib0030], [@bib0031], [@bib0032]. Screening was done with either plain radiographs or MRI. Our model assumed that only the pelvis and proximal femur would be imaged, (detecting he majority of chondrosarcomas). Lesions representing false-positives were not initially analysed in the base-model.Fig. 2Structure of the HME screening model. Reflecting current best-practice guidelines in the management of bone sarcomas, a positive screen result will require a diagnostic work-up comprising a clinical examination and a CT-guided biopsy [@bib0014].Fig. 2.

3.4. Model results {#sec0013}
------------------

Our screening model indicated that it would take 3.9 years of screening to identify a single case of malignant change if all HME patients were screened ([Table 1](#tbl0001){ref-type="table"}). The number of years of screening needed to detect a chondrosarcoma increased as the base population screened became smaller.Table 1Screening results and cancers induced by radiation in an X-ray screening programme.Table 1Scan strategy (age 20--40 years)All HME patients[c](#tb1fn3){ref-type="table-fn"}EXT1 patientsEXT1 male patientsPopulation in this cohort (n)28814483Lifetime risk of CS (%)469Years needed to pick up 1 CS of pelvis/proximal femur (n)3.865.095.90CS mortality rate (%)[a](#tb1fn1){ref-type="table-fn"}20.5(25)[b](#tb1fn2){ref-type="table-fn"}30.8(37.5)[b](#tb1fn2){ref-type="table-fn"}46.1 (56.3)[b](#tb1fn2){ref-type="table-fn"}Radiation induced cancers (n) [@bib0033]0.6450.3240.145CS detected by screening program (n)5.183.933.39Ratio of cancer picked up: cancer induced100:12100:8100:4[^1][^2][^3]

The chondrosarcoma mortality rates in the general HME cohort would become 20.5% with screening (compared to 25% without screening) and 46.1% in the EXT1 male patient cohort with screening (compared to 56.3% without screening). The cumulative radiation dose from 20 years of X-rays is 12mSv [@bib0033]. For every 100 chondrosarcomas picked up among the general HME population via plain radiography, a further 12 cancers would be induced by its radiation effects. The relative number of cancers induced by radiation decreased in the EXT1 subgroup and further decreased in the EXT1 male subgroup ([Table 1](#tbl0001){ref-type="table"}).

3.5. Cost-effectiveness analysis {#sec0014}
--------------------------------

The number of life-years gained increased as the screening strategy targeted a more select group of patients, from 5.2 life-years in X-ray screening of all HME patients to 13.8 life-years in X-ray screening of the EXT1 male population and from 11.8 life-years in MRI screening of all HME patients to 17.3 life-years in the EXT1 male population. The cost per life-year reduced significantly as a more select group of patients was targeted, from £53,392 in MRI screening of all HME patients to £10,494 in MRI screening of the EXT1 male population.

Plain radiographs screening resulted in a low cost / life-year gained, ranging from £19,013 for all HME patients to £2084 for EXT1 males. When X-ray and MRI screening modalities were compared, MRI produced an ICER of £80,218 per life-year when applied to all HME patients ([Table 2](#tbl0002){ref-type="table"}).Table 2Results of the different screening strategies.Table 2Scan strategyCS detected (n)CS deaths (n)Radiation induced cancer deaths[a](#tb2fn1){ref-type="table-fn"}Discounted (£)[b](#tb2fn2){ref-type="table-fn"}Life-years gainedCost of program (£)Cost/life year gained (£)ICER[c](#tb2fn3){ref-type="table-fn"} (£)All HME ptsAnnual X-ray5.181.060.1325.1597,91619,013--Annual MRI5.181.06--11.75627,35853,39280,218EXT1 ptsAnnual X-ray3.931.210.0998.2449,3845993--Annual MRI3.931.2113.19313,96923,80353,451EXT1 male ptsAnnual X-ray3.401.570.06613.8328,8292084--Annual MRI3.401.57--17.28181,35110,49444,209[^4][^5][^6]

3.6. Psychological impact of false-positives {#sec0015}
--------------------------------------------

Our model predicts 0.11 false-positives in the general HME population which translated into a marginal extra cost of £25 per life-year gained. The impact of false-positives on cost effectiveness decreased as the base-population became smaller ([Appendix B.2](#tbl0006){ref-type="table"}).

4. Discussion {#sec0016}
=============

Our systematic review showed that there was a scarcity of good quality studies on chondrosarcoma transformation in HME. In the studies that were identified, the incidence of chondrosarcoma transformation in the general HME population averaged 4%, with 75.2% occurring between ages 20--40 and 56.2% were located in the pelvis and proximal femur.

Based on the systematic review, a model was developed for screening to be done with either X-ray or MRI between ages 20--40 and concentrating on the pelvis and proximal femur. Our model suggests that screening the general HME population benefits the largest population of patients. However, when the NICE willingness-to-pay threshold of £30,000 per life-year gained was applied, a MRI screening strategy became cost-ineffective in the complete HME cohort. However x-ray screening was more cost-effective at £19,013 per life-year gained. When compared to the UK breast cancer screening program which yielded 1 life-year at £7357, screening became cost-effective only when using X-ray on patients with higher-risk profiles (EXT1 or EXT1 male patients) [@bib0022].

Nevertheless, we believe that MRI-screening becomes favourable if reasonable assumptions on increased effectiveness of MRI-screening are added to the model. We calculated that in the general HME cohort, MRI screening must produce an absolute improvement in chondrosarcoma mortality rates of 16.9% in order for cost per life-year gained to be \< £7,357. Our base-model was developed with the concept that screening would enable a lesion to be picked up before it reached 10 cm in size [@bib0018]. This is a very conservative estimate as annual screening could allow growing lesions to be picked up at 1--2 cm, making a 16.9% improvement in chondrosarcoma mortality rate attainable.

Our model detects cancers close to the peak of the individual\'s economical productivity. Detecting a cancer early also reduces treatments and treatment-associated morbidity. However, quality-adjusted-life-years (QALY) gained are difficult to estimate accurately without a pilot study. MRI scans might hence be more cost-effective than this report implies.

We acknowledge that MRIs are more expensive than X-rays. However, the model highlighted an important trade-off in an X-ray screening program: for every generation of HME patients (*n* = 288) screened 20 times over a 20 year period, the associated exposure to X-rays induced 0.65 cancers. This compares to the breast cancer program, where in the same number of patients screened 6 times over 20 years, only 0.02 fatal breast cancers were induced [@bib0023]. One reason for this difference is that our model only picks up 5.2 cancers in the general HME population, making the relative number of radiation-induced cancers significant.

We also acknowledge that our base-screening model will fail to detect the appendicular chondrosarcomas and also ribs and spine chondrosarcomas. However, appendicular chondrosarcomas should be more easily palpable on clinical examination [@bib0001], [@bib0007]. In order to detect rib and spine chondrosarcomas, a new 3-part coronal MRI protocol from the cervical spine to proximal femur could be developed. Because we are scanning for surveillance rather than diagnostic purposes, reducing the number of sequences and a widened field of view in the new protocol would reduce costs without sacrificing diagnostic sensitivity. The new MRI costing might hence not vary much from our existing model\'s costing [@bib0034].

There is an attractive alternative in the form of whole-body MRI techniques as these theoretically pick up 100% of chondrosarcomas [@bib0035]. However, conventional MRI systems are limited in performing whole-body scans and require patient repositioning [@bib0036]. The use of dedicated whole-body MRI scanners defeats the purposes of a screening programme where patients should be screened locally [@bib0035].

Another reason for proposing MRI over X-rays is that the orthopaedic literature might be under-reporting the incidence of spine exostoses because these come under the care of neurosurgeons [@bib0037], [@bib0038], [@bib0039]. Our hand-search of neurosurgical journals showed that on average, 60% of their HME cohorts had coincidental intra-spinal exostoses on MRI [@bib0037], [@bib0038], [@bib0039]. This is much higher than previously thought and indicates that the spine could be an important site for chondrosarcoma development [@bib0037], [@bib0038], [@bib0039]. We calculated that a 9.2% increase in spine chondrosarcomas would be sufficient to cause the cost per life-year gained with our current X-ray model in the general HME cohort go beyond the £30,000 NICE threshold.

Our model might has shown that screening EXT1 males only was the most cost effective at £10,494 per life-year gained and that it would cost 3--4 times more to gain one life-year in an EXT1 female. However, this evokes ethical issues: the prognosis for early chondrosarcomas is equally good in both genders, giving no reason beyond of financial costs to discriminate against screening females [@bib0010], [@bib0018], [@bib0040].

Our analysis has some limitations that must be acknowledged. Firstly, our systematic review revealed that there were only a limited number of small studies available. We acknowledge that this has made our model highly sensitive to parameters like incidence of malignant change and chondrosarcoma sites. We were unable to quantify biasness in each study and adjust for this in a statistical analysis because of the heterogeneity of data collected. However, Grimer\'s study had a large patient number (*n* = 719) which reduced our model\'s sensitivity to chondrosarcoma sites from smaller studies [@bib0041]. Secondly, all probabilities used to populate the model are estimates derived from the literature. Such estimates carry inherent uncertainty, as does using a hypothetical cohort. Thirdly, a low risk (0.03%) of gynaecological malignancies has been reported after exposure to high levels of pelvic radiation [@bib0042], [@bib0043], [@bib0044]. Our model may not have accurately identified incidence and survival rates from gynaecological malignancies which are themselves based on extrapolations from higher doses of irradiation. Last but not least, our model did not consider how a false-positive diagnosis might affect compliance in further screening rounds. We have shown however, that life-years lost due to anxiety are very marginal and believe the same to be true in terms of compliance rates. It is clear that more studies are needed to delineate the epidemiology of chondrosarcoma transformation in HME. A pilot study of an MRI scan of the pelvis and proximal femur could be commenced on a small number of HME patients. This identifies the minimum number of sequences and vision of field needed to detect chondrosarcomas. Radiology input is needed to develop the MRI protocol which scans from cervical spine to proximal femur and this also piloted.

5. Conclusion {#sec0017}
=============

While this model-based preliminary analysis is not intended to produce definitive conclusiveness, it does show that there is a case for annual screening of malignant transformation in HME patients. It also calculates the marginal gains and losses from screening different populations. Based on this report, we recommend that the screening programme should be an annual MRI scan encompassing all HME patients between ages 20--40. However, this report produced no definite conclusion on anatomical site to target. A specifically designed protocol which enables doctors to target more anatomical sites (from cervical spine to proximal femur) could prove more cost-effective.

Appendix A.1 {#sec0024}
============

MEDLINE VIA PUBMED (1948 -- February 2015) / EMBASE VIA PUBMED (1980 --February 2015): 1. exp exostoses, multiple hereditary/2. HME.tw; 3. multiple cartilaginous exostos\$.tw; 4. diaphyseal aclasis.tw; 5. osteochondroma\$.tw; 6. 1 or 2 or 3 or 4 or 5; 7. exp chondrosarcoma/; 8. exp mesenchymal chondrosarcoma/; 9. exp bone neoplasm/; 10. 7 or 8 or 9; 11. Aged/; 12. Age distribution/; 13. Adult/; 14. Child/; 15. Child, preschool/; 16. Infant/; 17. 11 or 12 or 13 or 14 or 15 or 16; 18. Male/; 19. Female/; 20. Sex/; 21. 18 or 19 or 20; 22. Exostosin-1.tw; 23. EXT-1.tw; 24. Exostosin-2.tw; 25. EXT-2.tw; 26. 22 or 23 of 24 or 25; 27. 6 and 10; 28. 17 and 21 and 26 and 27

CINAHL VIA EBSCO HOST (1937 -- February 2015): 1. multiple hereditary exostos\*; 2. chondrosarcoma; 3. age OR adult OR child OR infant; 4. gender OR sex; 5. ''exostosin-1'' OR ''exostosin-2''; 6. and/1--5.Appendix A.2Description of all studies that met the inclusion criteria.Appendix A2StudyType of studyNo. of patientsDistribution of EXT1 (%)Time periodAverage follow-up (months)Incidence of chondrosarcoma Transformati on^a^Males (%)Anatomic location of chondrosarcoma transformation (%)Age of diagnosis^b^*HumerusScapulaRibs and spineIlium and pubisProx femurDist femurTibia and fibula*Black et al. [@bib0012]*Longitudinal general population*35--1968--19882400 (0%)NANANANANANANANANAAltay et al. [@bib0005]*Case control*92--1986--200493.610(9.2%)20.08.316.78.325.016.716.78.335.9Wuisman et al. [@bib0006]*Case control*288--1972--199483.817(5.9%)76.56.817.213.837.917.23.43.434.0 (19--74)Clement et al. [@bib0007]*Case control*17261.71996--2000967(4.1%)85.714.128.128.114.314.300--Legeai-Mallet et al. [@bib0004]*Case control*17541.01955--19951021(0.6%)10000010000035.0Exner and Suter [@bib0024]*Case control*45--1971--20012403(6.7%)66.7033.3066.700025.0 (20--30)Pierz et al. [@bib0025]*Case control43*36.51991--20011010(0%)NANANANANANANANANAVanhoenacker et al. [@bib0019]*Case control*311001968--19982111(3.2%)10000010000025.0Suzaki et al. [@bib0026]*Case control*1457.11963--1984891(7.1%)10000010000030.0Grimer et al.^c^[@bib0041]*Case control*719--ongoingongoingNA56.08.016.08.048.08.08.04.037.4 (22--67)Schmale et al. [@bib0001]Cross-sectional113431994NA1(0.88%)10000010000041.0Ahmed et al. [@bib0013]Cross-sectional184442001NA46(25.1%)45.72.210.813.050.06.52.26.534.9 (15--77)Garrison et al. [@bib0027].Cross-sectional183--1981NA35(19.1%)65.78.611.414.345.75.705.730.7 (15--68)Voutsinas and Wynne-Davies [@bib0028]Cross-sectional180--1995NA5(2.8%)80.020.00060.0020.0032.0 (30--40)Wicklund et al. [@bib0029]Cross-sectional116--1983NA1(0.87%)10000100000025.0Gordon et al. [@bib0030]Case repor37--1981921(2.7%)10010000000023.0Kivioja et al. [@bib0031]Case repor184--19991454(8.3%)50.050005000037.7 (24--52)Crandall et al. [@bib0032]Case repor180--19831620(0%)NANANANANANANANANA[^7][^8][^9][^10][^11]Appendix A.3Costs involved in basic HME screening and subsequent diagnostic workup.Appendix A3Procedurecost (£)One part (pelvis) MRI108.72Plain film (pelvis)16.71CT guided biopsy150Clinical examination by surgeon80Administrative costs (notifying patient of results and recall)3.50Radiological visit (0.5 h): personal time 6.24\*6.24\*[^12]Appendix A.4Methodological quality of all studies included in this report as per NOS scale.Appendix A4Methodological quality of longitudinal general population studies included in this systematic reviewStudyAdequate definition of HME study group[b](#tb5fn2){ref-type="table-fn"}Follow up[c](#tb5fn3){ref-type="table-fn"}Blinding of researchers to outcome (i.e. chondrosarcoma transformation)Method of chondrosarcoma diagnosis[d](#tb5fn4){ref-type="table-fn"}Bovee [@bib0008]\*\*Methodological quality of case-control studies included in this systematic reviewStudyRepresentativeness of HME study group[a](#tb5fn1){ref-type="table-fn"}Adequate definition of HME study group[b](#tb5fn2){ref-type="table-fn"}Follow up [c](#tb5fn3){ref-type="table-fn"}Blinding of researchers to outcome (i.e. chondrosarcoma transformation)Method of chondrosarcoma diagnosis[d](#tb5fn4){ref-type="table-fn"}Altay et al. [@bib0005]\*\*\*Wuisman et al. [@bib0006]\*\*Clement et al. [@bib0007]\*\*\*Legeai-Mallet et al. [@bib0004]\*\*Pierz et al. [@bib0025]\*\*\*Suzaki et al. [@bib0026]\*\*NANAHealth [@bib0021]\*\*\*Garrison et al. [@bib0027]\*\*\*Grimer et al.[e](#tb5fn5){ref-type="table-fn"}[@bib0041]\*\*\*\*Methodological quality of cross-sectional studies included in this systematic reviewStudyRepresentativeness of HME study group[a](#tb5fn1){ref-type="table-fn"}Adequate definition of HME study group[b](#tb5fn2){ref-type="table-fn"}Blinding of researchers to outcome (i.e. chondrosarcoma transformation)Method of chondrosarcoma diagnosis[d](#tb5fn4){ref-type="table-fn"}Grimer et al. [@bib0014]\*\*Porter et al. [@bib0009]\*\*Voutsinas et al. [@bib0028]\*\*Wicklund et al. [@bib0029]\*\*Garrison et al. [@bib0027]\*\*Methodological quality of case series included in this systematic reviewStudyAttempt to include \> 5 generations of HME family[a](#tb5fn1){ref-type="table-fn"}Adequate definition of HME study group[b](#tb5fn2){ref-type="table-fn"}Follow up[c](#tb5fn3){ref-type="table-fn"}Method of chondrosarcoma diagnosis[d](#tb5fn4){ref-type="table-fn"}Kivioja et al. [@bib0031]\*\*\*\*Crandall et al. [@bib0032]\*\*\*\*Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation [@bib0033]\*\*\*NA[^13][^14][^15][^16][^17]Appendix B.1Incidence of chondrosarcoma transformation by study author.Appendix B.1:Appendix B.2Impact of short-term anxiety on cost-effectiveness.Appendix B2:MRI scan strategy[a](#tb6fn1){ref-type="table-fn"}False-positive CS detected in a 20 year programAnxiety per falsepositive result (life years)[b](#tb6fn2){ref-type="table-fn"}Revised cost/life-year gained (£)All HME0.110.05£ 53,417Patients age 20--40 years0.10£ 53,442EXT 1 patients0.080.05£ 23,8100.10£ 23,820EXT1 malepatients0.060.05£ 10,4970.10£ 10,500[^18][^19]
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[^1]: screening confers an 18% survival advantage at all-time points and in all age-groups.

[^2]: (CS mortality rates without screening are bracketed)

[^3]: Given a hypothetical cohort of 1150 HME patients it is calculated that 25% (288 patients) will be between the ages 20--40 years.

    Radiation induced cancers were calculated from a US report to assess health risks from radiation [@bib0033]

    Abbreviations: CS, chondrosarcoma

[^4]: Assume that all radiation induced cancers were chondrosarcomas of the pelvis/proximal femur

[^5]: Discounted at the rate of 3.5% per annum

[^6]: ICER is derived by dividing the incremental cost of the more costly screening modality by the difference in life-years gained.

    Abbreviations: CS, chondrosarcoma

[^7]: \- Data not available

[^8]: ^a^ Result expressed as absolute number (percentage in brackets)

[^9]: ^b^ Where it allows, the result is expressed as mean age (with range of ages in brackets)

[^10]: NA: data not applicable because there were no chondrosarcomas in that study

[^11]: ^c^ unpublished study from Mr Robert Grimer, Royal Orthopaedic Hospital in Birmingham. Data collection is still ongoing and some information unavailable.

[^12]: Estimated from median wage for a full-time 20--40 year old who worked 40 h a week [@bib0022].

[^13]: Studies received a \* if HME patients were entered consecutively or at random into the study.

[^14]: Studies received a \* if the HME study group was adequately defined with either \> 1person extracting a single record at a time or if references were made to primary record sources like X-rays, MRIs or biopsies.

[^15]: Studies received a \* if HME patients were followed up for at least 2 years and \*\* if patients were followed up for at least 5years.

[^16]: Studies received a \* if the diagnosis of chondrosarcomas were confirmed using biopsy.

[^17]: Unpublished study from Mr Robert Grimer, Royal Orthopaedic Hospital in Birmingham. Data collection is still ongoing.

    Columns were left blank if no \* could be awarded

    NA no chondrosarcomas developed in this study

[^18]: The false positive rate in MRIs was assumed to be 2% based on earlier mentioned MRI validation studies which showed that MRI scans had 98% sensitivity.

[^19]: The model had been re-run simulating the effect of different levels of anxiety on cost-effectiveness. This anxiety was defined in life-years lost (0.05 life-years and 0.10 life-years). The life-years lost from anxiety mimicked the anxiety levels in the breast cancer screening program.

    Abbreviations: CS, chondrosarcoma
